6.
Park J, Bagatell R, Cohn S, Pearson A, Villablanca J, Berthold F
. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017; 35(22):2580-2587.
PMC: 5676955.
DOI: 10.1200/JCO.2016.72.0177.
View
7.
Mordant P, Loriot Y, Lahon B, Castier Y, Leseche G, Soria J
. Minimal residual disease in solid neoplasia: New frontier or red-herring?. Cancer Treat Rev. 2011; 38(2):101-10.
DOI: 10.1016/j.ctrv.2011.04.014.
View
8.
Coustan-Smith E, Sancho J, Hancock M, Razzouk B, Ribeiro R, Rivera G
. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002; 100(7):2399-402.
DOI: 10.1182/blood-2002-04-1130.
View
9.
Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M
. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22.
DOI: 10.1373/clinchem.2008.112797.
View
10.
Tolbert V, Matthay K
. Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res. 2018; 372(2):195-209.
PMC: 5918153.
DOI: 10.1007/s00441-018-2821-2.
View
11.
Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K
. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303.
PMC: 2650389.
DOI: 10.1200/JCO.2008.16.6876.
View
12.
Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano G, De Sio L
. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl. 2004; 93(445):6-11.
DOI: 10.1111/j.1651-2227.2004.tb03048.x.
View
13.
Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G
. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97.
PMC: 2650388.
DOI: 10.1200/JCO.2008.16.6785.
View
14.
Uemura S, Ishida T, Mon Thwin K, Yamamoto N, Tamura A, Kishimoto K
. Dynamics of Minimal Residual Disease in Neuroblastoma Patients. Front Oncol. 2019; 9:455.
PMC: 6558004.
DOI: 10.3389/fonc.2019.00455.
View
15.
Huggett J, Foy C, Benes V, Emslie K, Garson J, Haynes R
. The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments. Clin Chem. 2013; 59(6):892-902.
DOI: 10.1373/clinchem.2013.206375.
View
16.
Brodeur G
. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16.
DOI: 10.1038/nrc1014.
View
17.
Brownhill S, Burchill S
. PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma. Pract Lab Med. 2017; 7:41-44.
PMC: 5575362.
DOI: 10.1016/j.plabm.2016.04.003.
View
18.
Lin K, Uemura S, Mon Thwin K, Nakatani N, Ishida T, Yamamoto N
. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood. Transl Oncol. 2021; 14(8):101019.
PMC: 8138775.
DOI: 10.1016/j.tranon.2021.101019.
View
19.
Marachelian A, Villablanca J, Liu C, Liu B, Goodarzian F, Lai H
. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clin Cancer Res. 2017; 23(18):5374-5383.
DOI: 10.1158/1078-0432.CCR-16-2647.
View
20.
Seeger R, Reynolds C, Gallego R, Stram D, Gerbing R, Matthay K
. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2000; 18(24):4067-76.
DOI: 10.1200/JCO.2000.18.24.4067.
View